KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.50

Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes.

Rafael Oliveira, Tarje Halvorsen, Kristin Killingberg, Elisabeth Fritzke Emdal, Vibeke Grotnes Dale, Bjørn Henning Grønberg, Pål Sætrom

Lung Cancer 221 109606

PMID42691846
PMCID-
DOI10.1016/j.lungcan.2026.109606
发表日期2026-09-03
入排依据:未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
摘要

摘要

BACKGROUND: Concurrent chemoradiotherapy (CRT) remains the primary treatment for limited stage (LS) small cell lung cancer (SCLC). Although most patients respond, the majority relapse and die from the disease, and treatment-related toxicity is common. Molecular subtyping has been extensively investigated in SCLC, but its clinical relevance remains uncertain, and most studies have focused on systemic treatment of extensive-stage SCLC. We analysed baseline tumor samples from a subset of participants (n = 77) in a randomized trial (n = 170) comparing high-dose (60 Gy/40 fractions) with standard-dose (45 Gy/30 fractions) twice-daily thoracic radiotherapy given concurrently with platinum-etoposide chemotherapy for LS SCLC, aiming to characterize molecular subtypes of LS SCLC and evaluate their association with time to progression (TTP) and overall survival (OS). METHODS: Molecular subtypes were defined in 81 samples using non-negative matrix factorization on gene expression data, supported by differential expression and known SCLC markers. RESULTS: Inflamed subtypes were associated with better treatment outcomes. Univariable analysis indicate that SCLC-I-NE (inflamed neuroendocrine) was associated with longer TTP (HR 0.10, 95 % CI 0.01-0.80, p = 0.03), and SCLC-I-nNE (inflamed non-neuroendocrine) was associated with improved OS (HR 0.16, 95 % CI 0.03-0.77, p = 0.02). By contrast, SCLC-N (NEUROD1-driven) was consistently associated with both shorter TTP (HR 6.90, 95 % CI 1.49-31.92, p = 0.01) and OS (HR 4.89, 95 % CI 1.24-19.21, p = 0.02). CONCLUSIONS: For LS SCLC patients receiving CRT, tumors of inflamed subtypes were associated with improved outcomes, whereas SCLC-N tumors were linked to unfavorable TTP and OS.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。